TNFRSF11B

TNFRSF11B Full Name

tumor necrosis factor receptor superfamily, member 11b

TNFRSF11B Introduction

TNFRSF11B, also known as osteoprotegerin (OPG), is a secreted member of the tumor necrosis factor receptor superfamily that plays a central role in regulating bone remodeling and maintaining skeletal stability. For many researchers and clinicians, a major challenge in bone-related diseases is understanding and controlling excessive bone resorption that leads to fragility and structural imbalance. TNFRSF11B addresses this issue by functioning as a decoy receptor for RANKL, thereby blocking its interaction with the RANK receptor on osteoclast precursors. This interruption effectively inhibits osteoclast differentiation and activity, reducing bone degradation. Because of its critical position in the RANK/RANKL/OPG signaling axis, TNFRSF11B has become a key molecular target for studying bone metabolism and for developing therapies aimed at preventing pathological bone loss.

In addition to its physiological role in bone homeostasis, TNFRSF11B has emerged as an important regulator in cancer biology, particularly in tumors associated with bone environments such as osteosarcoma. One of the persistent pain points in oncology is identifying molecules that not only correlate with tumor aggressiveness but also actively drive disease progression. Elevated expression of TNFRSF11B has been linked to increased tumor cell proliferation, migration, and invasion. Mechanistically, it contributes to malignant transformation by modulating signaling pathways such as PI3K/Akt/mTOR and by supporting metabolic adaptations like enhanced glycolysis. Functional studies have demonstrated that reducing TNFRSF11B expression can significantly suppress tumor growth and metastatic potential, suggesting that it may serve as both a prognostic biomarker and a therapeutic target in cancer treatment strategies.

The importance of TNFRSF11B is further underscored by its involvement in genetic and tissue-specific disorders, where its dysfunction leads to clinically significant outcomes. Loss-of-function mutations in TNFRSF11B are associated with severe skeletal diseases such as juvenile Paget's disease, characterized by accelerated bone turnover, deformities, and increased fracture risk. These mutations impair the normal inhibitory function of OPG, resulting in uncontrolled osteoclast activity. Moreover, genetic variations in TNFRSF11B have been implicated in conditions like orthodontic-induced external apical root resorption, where imbalances in local bone remodeling affect dental treatment outcomes. Together, these findings highlight TNFRSF11B as a critical regulator across multiple biological systems, making it highly relevant for disease mechanism research, risk assessment, and the development of targeted therapeutic interventions.

Alternate Names for TNFRSF11B

TNFRSF11B; tumor necrosis factor receptor superfamily, member 11b; OPG,osteoprotegerin; tumor necrosis factor receptor superfamily member 11B; OCIF; TR1; MGC29565; OCIF; OPG; Osteoclastogenesis Inhibitory Factor

• 1.Xu J. The role of tumor necrosis factor receptor superfamily in cancer: insights into oncogenesis, progression, and therapeutic strategies. NPJ Precis Oncol. 2025, 9(1):275.
  2.Liu J, et al.; Construction of a 5-Gene super-enhancer-related signature for osteosarcoma prognosis and the regulatory role of TNFRSF11B in osteosarcoma. Transl Oncol. 2024, 47:102047.